

Medicine, and the Department of Pharmacology (P.S.), University Hospital of Nijmegen, Nijmegen, the Netherlands.

Address correspondence to Cees J.J. Tack, PO Box 9101, 6500 HB Nijmegen, the Netherlands. E-mail: c.tack@aig.azn.nl.

References

1. Howard BV, Howard WJ: LDL cholesterol and troglitazone therapy (Letter). *Diabetes Care* 21:2201–2202, 1998
2. Van de Vijver LPL, Kardinaal AFM, Van Duyvenvoorde W, Kruijssen DACM, Grobbee DE, Van Poppel G, Princen HMG: LDL oxidation and extent of coronary atherosclerosis. *Arterioscler Thromb Vasc Biol* 18:193–199, 1998
3. Regnström J, Nilsson J, Tornval P, Landou C, Hamsten A: Susceptibility to low density lipoprotein oxidation and coronary atherosclerosis in man. *Lancet* 339:1183–1186, 1992
4. Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC: Vitamin E consumption and the risk of coronary heart disease in men. *N Engl J Med* 328:1450–1456, 1993
5. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ: Randomised trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). *Lancet* 347:781–786, 1996
6. Kleinvelde HA, Hak-Lemmers HL, Hectors MP, de Fouw NJ, Demacker PN, Stalenhoef AF: Vitamin E and fatty acid intervention does not attenuate the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbits. *Arterioscler Thromb Vasc Biol* 15:290–297, 1995
7. Austin MA, King M-C, Vranizan KM, Krauss RM: Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk. *Circulation* 82:495–506, 1990
8. Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, Despres JP: Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. *Circulation* 95:1–4, 1997
9. Bredie SJ, de Bruin TW, Demacker PN, Kastelein JJ, Stalenhoef AF: Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability. *Am J Cardiol* 75:348–353, 1995
10. Huttunen JK, Manninen V, Manttari M, Koskinen P, Romo M, Tenkanen L, Heinonen OP, Frick MH: The Helsinki Heart Study: central findings and clinical implications. *Ann Med* 23:155–159, 1991
11. Maggs DG, Buchanan TA, Burant CF, Cline G, Gumbiner B, Hsueh WA, Inzucchi S, Kelley D, Nolan J, Olefsky JM, Polonsky KS, Silver D, Valiquett TR, Shulman GI: Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. *Ann Intern Med* 128:176–185, 1998
12. Schwartz S, Raskin P, Fonseca V, Graveline JF, the Troglitazone and Exogenous Insulin Study Group: Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. *N Engl J Med* 338:861–866, 1998

Erratum

Brown JB, Pedula K, Barzilay J, Herson MK, Latare P: Lactic acidosis rates in type 2 diabetes. *Diabetes Care* 21:1659–1663, 1998

Incorrect data were given in Table 1. The table is shown below, with the corrected data in bold.

Table 1—Frequency of lactic acidosis

	Mean age (years)	Person-years reviewed	Events reviewed	Identified lactic acidosis events		
				Confirmed	Possible	Borderline
KP-Northwest						
1993	63.5 ± 12.4	10,983	10	0	0	0
1994	63.7 ± 12.3	10,667	9	1	0	1
KP-Georgia						
1993	55.2 ± 8.5	3,803	6	0	2	—
1994	55.6 ± 8.7	4,027	12	0	1	—
KP-Hawaii						
1993	62.6 ± 10.8	4,710	13	1	0	1
1994	64.3 ± 10.9	7,236	25	2	0	1
Total						
1993	61.7 ± 11.4	19,506	29	1	2	1
1994	62.4 ± 11.3	21,930	46	3	1	2
Overall	—	41,436	75	4	3	3
Rate per 100,000 person-years	—	—	—	9.7	7.2	7.2
95% CI	—	—	—	0.2 to 19.1	–1.0 to 15.4	–1.0 to 15.4

Data are means ± SD or n.